Abstract
Despite the important role of pyrazinamide in tuberculosis treatment, little is known about the mechanism of pyrazinamide-induced hepatotoxicity. We inhibited xanthine oxidase in HepG2 cells by using a nontoxic concentration of allopurinol, a well-known xanthine-oxidase inhibitor. This increased in vitro pyrazinamide toxicity in HepG2 cells, which suggests that the hydroxy metabolites of pyrazinamide are probably not fully responsible for pyrazinamide-induced toxicity, and that pyrazinoic acid and pyrazinamide are involved in pyrazinamide toxicity.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Allopurinol / pharmacology*
-
Antitubercular Agents / adverse effects
-
Antitubercular Agents / therapeutic use*
-
Area Under Curve
-
Cell Survival / drug effects
-
Chemical and Drug Induced Liver Injury / enzymology
-
Chemical and Drug Induced Liver Injury / etiology*
-
Chemical and Drug Induced Liver Injury / metabolism
-
Drug Synergism
-
Enzyme Inhibitors / pharmacology*
-
Hep G2 Cells
-
Humans
-
Pyrazinamide / toxicity*
-
Statistics, Nonparametric
-
Xanthine Oxidase / antagonists & inhibitors*
-
Xanthine Oxidase / metabolism
Substances
-
Antitubercular Agents
-
Enzyme Inhibitors
-
Pyrazinamide
-
Allopurinol
-
Xanthine Oxidase